
Sign up to save your podcasts
Or
The process of finding new treatments for Alzheimer’s disease is one of trial and error — and every “failed” trial generates invaluable new data to help researchers and drug developers understand what works, what doesn’t, and why. On Wednesday, January 24th, at 10:00 a.m. PT/1:00 p.m. ET, drug trial participant Bill Sasse, who was a participant in Eli Lilly’s clinical trial of experimental monoclonal antibody drug solanezumab, joins Being Patient Live Talks to discuss his experience with the drug trial. In March of 2023, solanezumab ultimately failed to hit its benchmarks in slowing cognitive decline and the trial was discontinued.
4.6
99 ratings
The process of finding new treatments for Alzheimer’s disease is one of trial and error — and every “failed” trial generates invaluable new data to help researchers and drug developers understand what works, what doesn’t, and why. On Wednesday, January 24th, at 10:00 a.m. PT/1:00 p.m. ET, drug trial participant Bill Sasse, who was a participant in Eli Lilly’s clinical trial of experimental monoclonal antibody drug solanezumab, joins Being Patient Live Talks to discuss his experience with the drug trial. In March of 2023, solanezumab ultimately failed to hit its benchmarks in slowing cognitive decline and the trial was discontinued.
225,926 Listeners
14 Listeners
111,059 Listeners
14,967 Listeners
156 Listeners
65 Listeners
28,642 Listeners
15,495 Listeners
19,698 Listeners
16 Listeners